The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa

NCT ID: NCT07143981

Last Updated: 2026-01-23

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 20 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2026-01-15
• Study Completion Date: 2027-08-31

Brief Summary

Anorexia Nervosa (AN) is a severe, debilitating and potentially life threatening illness that is difficult to treat. A cardinal symptom of AN is the mistaken belief on the part of the individuals that they are overweight and must continue to restrict intake. This fixed false belief is a detrimental factor to recovery. It is known that AN involves disturbance in the gut microbiome (GM; the microbes that live in the lower intestinal tract). The GM also affects how one thinks and makes food choices - there appears to be a direct link between the GM and how the brain functions. This connection is thought to occur through chemical processes that convey information from the gut to the brain. It is known that fecal microbiome transplant (FMT) has been useful in treating several illnesses, including several mental illnesses. The investigators intend to deliver FMT to individuals with AN to determine the extent to which this modifies their GM, their biochemistry, their thinking processes and their moods and emotions. The investigators believe this will illuminate important aspects of AN that keep the illness in place, and that this will uncover useful approaches to better treat it.

Detailed Description

The overall objective is to determine FMT's acceptability and the extent and means by which it helps patients with AN, restricting type. The investigators hypothesize that FMT will lead to diversification of the GM, improved metabolic and immunological status and reduced cognitive and psychiatric symptoms in patients with AN, details never investigated before. This will be due to FMT's ability to impart healthy microorganisms into the lower intestines and, thereby, improve GBM-axis signaling that may contribute to maintaining AN. The investigators propose that this will result in measurable improvement in cognitive distortions about weight, leading to reduced AN symptomatology, breaking the weight loss/AN cycle.

Specific Aims & Hypotheses

This is a one-group, pre-/post-intervention trial of FMT in AN-restricting type, with 1-week, 3-week and 3-month follow up, administered before specialized eating disorders treatment. The hypotheses are:

1. FMT will result in a sustained increase diversity of microbes with the metabolomic characteristics of increased short-chain fatty acids and bacteriophage composition compared with pre-treatment, as determined by targeted metabolomic approaches.

2. FMT will improve immune profiles, reducing IL6, IL1b and the proportion of Th17 cells, along with an increase in repair cytokines such as TARC, IL4, IL13 and BDNF and Th2 cells.

3. FMT will significantly improve cognitive and affective functioning, including task-switching efficiency, food aversion and obsessional thinking about weight, punishment and reward sensitivity, depression and anxiety symptomatology, and AN symptom severity.

This is a prospective, longitudinal, single-arm, pre-post intervention. Variables will be compared using repeated-measures analyses with each participant as their own comparator.

Conditions

Anorexia Nervosa

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Active treatment

Receiving FMT

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• meet DSM 5 criteria for AN, restricting type, moderate or higher severity, as indicated by a BMI<17
• Participants must we willing and able to swallow FMT capsules without vomiting
• Able to read and understand conversational English

Exclusion Criteria

1. Medical or psychiatric instability needing hospitalization

2. Patients with AN binge/purge type

3. Use of antibiotics or probiotics in the month prior to treatment

4. Regular oral steroid use, or potent topical steroid use on large sections of skin

5. Chronic immune compromise and chronic illness affecting the intestinal tract or metabolic health

6. Pregnancy or intended pregnancy over the time of study

7. Patients enrolled in any treatment program that involves refeeding

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Western University, Canada

OTHER

Sponsor Role: collaborator

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elizabeth Osuch

Role: PRINCIPAL_INVESTIGATOR

London Health Sciences Centre

Locations

London Health Sciences Research Institute

London, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Michael Wammes

Role: CONTACT

michael.wammes@lhsc.on.ca

519-646-6000 ext. 65196

Medina Meddaoui

Role: CONTACT

medina.meddaoui@lhsc.on.ca

Facility Contacts

Beth Osuch

Role: primary

elizabeth.osuch@lhsc.on.ca

519-685-8500 ext. 65188

Related Links

https://pubmed.ncbi.nlm.nih.gov/35743087/

Provides theoretical support for this project

https://pubmed.ncbi.nlm.nih.gov/38505265/

Provides theoretical support for this project

Other Identifiers

ANFMT-001

Identifier Type: -

Identifier Source: org_study_id